Angiogenic proteins are expressed by brain blood vessels in Alzheimer's disease
The DOI matches its Crossref record.
Abstract
Data are emerging to support the idea that mediators of angiogenesis are found in the Alzheimer's disease (AD) brain. The objective of this study is to compare the expression of the angiogenic mediators vascular endothelial growth factor (VEGF), angiopoietin, and matrix metalloproteinases (MMPs) in the microcirculation of AD patients and age-matched controls. Our results indicate that angiopoietin-2 and VEGF are expressed by AD- but not control-derived microvessels. AD-derived microvessels also release higher levels of MMP-2 and MMP-9 compared to controls. The data show that despite high levels of MMP-9, assessed by western blot, MMP-9 activity is not detectable in AD microvessels. In this regard we find high levels of the tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in AD, but not control vessels. Furthermore, we explore the ability of thrombin, previously shown to be present in AD microvessels, to affect TIMP expression in cultured brain endothelial cells and find that thrombin causes up regulation of TIMP-1. These data show that angiogenic changes occur in the microcirculation of the AD brain and suggest that if these changes are contributory to disease pathogenesis, targeting the abnormal brain endothelial cell would provide a novel therapeutic approach for the treatment of this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Grammas, P. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-26 · Cited by 432
“and integrins are all upregulated in the AD brain [54,93,108].”
BackgroundSelf-citationKalaria, R. N. (2010) · Nutrition Reviews · doi:10.1111/j.1753-4887.2010.00352.x · Cited by 290
Oxidative stress and β-amyloid protein in Alzheimer’s disease
Cai, Z., Zhao, B., & Ratka, A. (2011) · NeuroMolecular Medicine · doi:10.1007/s12017-011-8155-9 · Cited by 279
“Expression of MMPs is regulated at transcriptional, translational, and post-translational levels with tissue inhibitor of metallo- proteinase (TIMP) (Flex et al. 2006; Thirumangalakudi et al. 2006).”
BackgroundGovindpani, K., McNamara, L. G., Smith, N. R., Vinnakota, C., Waldvogel, H. J., Faull, R. L., & Kwakowsky, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050651 · Cited by 275
Evidence of angiogenic vessels in Alzheimer’s disease
Desai, B. S., Schneider, J. A., Li, J.-L., Carvey, P. M., & Hendey, B. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0226-9 · Cited by 153
“Furthermore, angiogenic mediators angiopoietin-2 and VEGF are released by microvessels isolated from AD brains in vitro (Thirumangalakudi et al. 2006).”
Desai Bradaric, B., Patel, A., Schneider, J. A., Carvey, P. M., & Hendey, B. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-011-0684-8 · Cited by 139
“…of neurodegenerative diseases and their animal models including Alzheimer’s disease (AD) (Desai et al. 2009; Pogue and Lukiw 2004; Schultheiss et al. 2006; Thirumangalakudi et al. 2006; Vagnucci and Li 2003), and multiple sclerosis (MS) (Holley et al. 2010; Kirk et al. 2004; Roscoe et al. 2009).”
BackgroundMarkers of neuroinflammation associated with Alzheimer’s disease pathology in older adults
Popp, J., Oikonomidi, A., Tautvydaitė, D., Dayon, L., Bacher, M., Migliavacca, E., Henry, H., Kirkland, R., Severin, I., Wojcik, J., et al. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.01.020 · Cited by 136
Blood-brain barrier leakage in Alzheimer’s disease: From discovery to clinical relevance
Nehra, G., Bauer, B., & Hartz, A. M. S. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108119 · Cited by 127
An Integrated View on Vascular Dysfunction in Alzheimer’s Disease
Klohs, J. (2019) · Neurodegenerative Diseases · doi:10.1159/000505625 · Cited by 111
Rivera, S., García-González, L., Khrestchatisky, M., & Baranger, K. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03178-2 · Cited by 111
Brain Endothelial Cells Synthesize Neurotoxic Thrombin in Alzheimer’s Disease
Yin, X., Wright, J., Wall, T., & Grammas, P. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090406 · Cited by 104
Self-citationGama Sosa, M. A., Gasperi, R. D., Rocher, A. B., Wang, A. C.-J., Janssen, W. G. M., Flores, T., Perez, G. M., Schmeidler, J., Dickstein, D. L., Hof, P. R., et al. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090482 · Cited by 92
Spampinato, S. F., Merlo, S., Sano, Y., Kanda, T., & Sortino, M. A. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14068 · Cited by 90
Brain microvasculature and hypoxia-related proteins in Alzheimer's disease.
(2011) · PubMed Central · Cited by 65
Endogenous and synthetic MMP inhibitors in CNS physiopathology.
Baranger, K., Rivera, S., Liechti, F. D., Grandgirard, D., Bigas, J., Seco, J., Tarrago, T., Leib, S. L., & Khrestchatisky, M. (2014) · Progress in Brain Research · doi:10.1016/b978-0-444-63486-3.00014-1 · Cited by 52
Hoyo-Becerra, C., Huebener, A., Trippler, M., Lutterbeck, M., Liu, Z. J., Truebner, K., Bajanowski, T., Gerken, G., Hermann, D. M., & Schlaak, J. F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083149 · Cited by 49
Endothelin-1 is Elevated in Alzheimer's Disease Brain Microvessels and is Neuroprotective
Luo, J., & Grammas, P. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091486 · Cited by 39
“Our previous work has documented that the cerebral microcirculation is altered and the brain endothelial cells exhibit an activated phenotype in AD [42,44].”
Self-citationDurrant, C. S., Ruscher, K., Sheppard, O., Coleman, M. P., & Özen, I. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2288-4 · Cited by 39
Hoerndli, F. J., Pelech, S., Papassotiropoulos, A., & Götz, J. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05618.x · Cited by 34
Paris, D., Ganey, N., Banasiak, M., Laporte, V., Patel, N., Mullan, M., Murphy, S. F., Yee, G.-T., Bachmeier, C., Ganey, C., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2586-10.2010 · Cited by 30
“The presence of angiogenic proteins such as VEGF and TIMP-1 in isolated AD microvessels has led to the supposition that the cerebral microvasculature is in a “proangiogenic state” in AD (Thirumangalakudi et al., 2006).”
BackgroundTarawneh, R. (2023) · Biomolecules · doi:10.3390/biom13050830 · Cited by 29
“Angiogenesis and vascular remodeling are impaired in AD as evidenced by altered expression profiles of several angiogenic factors, such as VEGF, vascular-restricted mesenchyme homeobox-2 (MEOX2), MMP-9, angiopoietin-2, integrins (αvβ3 and αvβ5), and the transferrin receptor, leading to vascular regression and abnormal…”
BackgroundPhosphorylated Tau 181 Serum Levels Predict Alzheimer’s Disease in the Preclinical Stage
Qin, W., Li, F., Jia, L., Wang, Q., Li, Y., Wei, Y., Li, Y., Jin, H., & Jia, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.900773 · Cited by 23
“ANG-2 has also been reported as upregulated in AD patients (Thirumangalakudi et al., 2006; Rocha de Paula et al., 2011).”
Background
Metadata
- Authors
- Thirumangalakudi, L., Samany, P. G., Owoso, A., Wiskar, B., & Grammas, P.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2006-09-08
- Volume
- 10
- Issue
- 1
- Pages
- 111-118
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W197140406
- Cited by
- 117
- References
- 0
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.